Comparative Pharmacology
Head-to-head clinical analysis: FERUMOXYTOL versus PROFERDEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERUMOXYTOL versus PROFERDEX.
FERUMOXYTOL vs PROFERDEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle that provides a source of iron for erythropoiesis. It is phagocytosed by macrophages of the reticuloendothelial system, and iron is released intracellularly to bind to transferrin and ferritin, replenishing iron stores.
PROFERDEX (iron dextran) is a colloidal solution of ferric hydroxide in complex with dextran, providing a source of iron for hemoglobin synthesis and erythropoiesis. Iron is incorporated into heme, which is essential for oxygen transport in red blood cells.
510 mg intravenously once, followed by 510 mg intravenously 3 to 8 days later for a total cumulative dose of 1020 mg. Administer as a slow IV injection at 1 mL/min (30 mg/min) undiluted or diluted in 50-200 mL normal saline.
100 mg intramuscular or intravenous every 3 to 7 days; may increase to 200 mg per dose.
None Documented
None Documented
Terminal elimination half-life is approximately 14-21 hours in healthy adults; prolonged in patients with iron deficiency anemia (up to 30 hours) due to increased iron utilization.
Terminal half-life approximately 20-30 hours in patients with normal hepatic function; prolonged in hepatic impairment. Clinical context: supports every-3-week dosing.
Ferumoxytol is eliminated primarily through the reticuloendothelial system, with the iron moiety incorporated into hemoglobin or stored as ferritin/hemosiderin. Minimal renal or biliary excretion of intact drug; <1% excreted unchanged in urine.
Primarily fecal (biliary excretion of iron from degraded RBCs, about 80-90%); renal excretion negligible (<5% unchanged).
Category C
Category C
Iron Replacement
Iron Replacement